Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease
This study has been withdrawn prior to enrollment.
Douglas T. Dieterich
Valeant Pharmaceuticals International, Inc.
Information provided by (Responsible Party):
Douglas T. Dieterich, Icahn School of Medicine at Mount Sinai
First received: July 30, 2012
Last updated: September 25, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Study Status:||This study has been withdrawn prior to enrollment.|
|Estimated Study Completion Date:||September 2015|
|Primary Completion Date:||September 2014 (Final data collection date for primary outcome measure)|